From: Using the needs of WHO to prioritise Cochrane reviews: The case of antipsychotic drugs
RCTs | Total number of people | Cochrane review | Reference | Up to date? | |
---|---|---|---|---|---|
Chlorpromazine | |||||
vs anticonvulsant agents | 2 | 118 | ✗ | ||
vs antidepressants | 12 | 732 | ✓ | [22, 23] | ✗ |
vs antihypertensive agents | 8 | 286 | ✗ | ||
vs antiparkinsonian agents | 3 | 80 | ✗ | ||
vs antituberculosis agents | 1 | 25 | ✗ | ||
vs barbiturates | 3 | 750 | ✗ | ||
vs benzodiazepines | 9 | 457 | ✓ | [24, 25] | ✗ |
vs mood stabilizers | 2 | 49 | ✓ | [26–28] | ✗ |
vs opioid agonist | 1 | 340 | ✗ | ||
vs opioid antagonist | 1 | 60 | ✗ | ||
Fluphenazine decanoate | |||||
vs antihypertensive agents | 1 | 17 | ✗ | ||
vs antituberculosis agents | 1 | 55 | ✗ | ||
Haloperidol | |||||
vs antiarrhythmic agents | 2 | 30 | ✗ | ||
vs antidepressants | 10 | 774 | ✓ | [22, 23] | ✗ |
vs antidopaminergic agents | 4 | 146 | ✗ | ||
vs antigout agents | 1 | 46 | ✗ | ||
vs antihypertensive agents | 3 | 122 | ✗ | ||
vs antineoplastic agents | 3 | 101 | ✗ | ||
vs antiparkinsonian agents | 8 | 265 | ✗ | ||
vs antiprogesterone agents | 1 | 80 | ✓ | [29] | ✗ |
vs benzodiazepines | 35 | 4012 | ✓ | [24, 25] | ✗ |
vs ethanol | 1 | 35 | ✗ | ||
vs glucose | 1 | unclear | ✗ | ||
vs mood stabilizers | 23 | 1648 | ✓ | [26–28] | ✗ |
vs stimulant agents | 1 | 20 | ✗ |